Soon after FDA warned the manufacturer involved in a massive nationwide recall of valsartan- and losartan-containing drugs, the recall is expanding. Find out why.
Formulary Watch
Latest News
All News
Advertisement
Two new therapies approved by FDA signal significant advancement in treating rare blood diseases.
Fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the aorta, FDA said in a new warning.
A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.
After an expanded recall of the blood pressure medication valsartan, FDA is warning the manufacturer of the carcinogenic ingredient involved.
Two major drug recalls in the last week include an expanded recall of a widely used blood pressure medication as well as over-the-counter infant ibuprofen.
Find out how healthcare organizations and analysts feel about new Medicare Part D proposals and drug pricing.
Here are the top 2 novel cancer drugs cleared by the agency.
FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.
Advertisement
FDA approved an autoinjector to treat rheumatoid arthritis and other diseases.
While some pharma makers have lowered drug prices and Express Scripts is pushing more branded manufacturers to lower list prices with its new National Preferred Flex Formulary, some manufacturers are raising drug prices.
Express Scripts’ new National Preferred Flex Formulary, which offers lower list prices on certain branded drugs, is a novel way to encourage pharma makers to lower prices.
Despite concerns about a new opioid that is reportedly 1,000 times more powerful than morphine, FDA recently approved the new painkiller.
Certain groups expressed “deep concern” over FDA allowing an OTC asthma inhaler to be sold again after it was removed from the market 7 years ago. Here’s why.
FDA approves the first new flu drug in 20 years. Here’s what’s different about it.
A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.
FDA recently stopped importation and sent warning letters to numerous online sellers of illegal opioids, oncology drugs and other medicines.
Pharmacy benefit managers, cardiologists, and others praised a pharma maker for significantly reducing the price of its high cholesterol drug.
A novel treatment for patients with moderate-to-severe asthma is now on the market.
A new indication for rivaroxaban (Xarelto) has been approved by FDA.
FDA approved a new antibiotic to treat community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.
Here are the top 3 new approvals from FDA.
While Teva Pharmaceutical’s new migraine prevention drug is unique, it faces competition from another major migraine treatment.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
3
7 takeaways from the MHE webinar on PBM reform and transparency
4
What employees may miss when they buy drugs directly online
5